Nispomeben (NRD.E1)
Painful Diabetic Peripheral Neuropathy (PDPN)
Phase 2bActive
Key Facts
About Novaremed
Novaremed is a Swiss biotech innovating in non-opioid pain management, targeting the high-unmet need in neuropathic pain conditions. Its lead asset, nispomeben, is a novel small molecule with a distinct mechanism of action, currently in an NIH-funded Phase 2b trial for diabetic neuropathy. The company is privately held, pre-revenue, and leverages strategic partnerships and grant funding to advance its clinical programs, positioning itself as a potential disruptor in the pain therapeutics market.
View full company profile